{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hiv-infection-aids/management/established-hiv-infection/","result":{"pageContext":{"chapter":{"id":"4c89980b-d988-5bb0-97eb-85427710fb28","slug":"established-hiv-infection","fullItemName":"Scenario: Established HIV infection","depth":2,"htmlHeader":"<!-- begin field d8b6f919-7c47-4251-943f-cf9912d45fd6 --><h2>Scenario: Established HIV infection</h2><!-- end field d8b6f919-7c47-4251-943f-cf9912d45fd6 -->","summary":"Covers the primary care management of HIV infection, and its complications and consequences.","htmlStringContent":"<!-- begin item 9ece6b2f-0f32-4365-8236-af2a4be6ee26 --><!-- begin field 48ada9f0-abb7-4bb3-90f9-acd900ab1ce1 --><p>From birth onwards.</p><!-- end field 48ada9f0-abb7-4bb3-90f9-acd900ab1ce1 --><!-- end item 9ece6b2f-0f32-4365-8236-af2a4be6ee26 -->","topic":{"id":"6c2470d2-9bde-5a16-91a3-b5ed74ce2d2b","topicId":"23723770-8df0-4d05-aa4f-806db67f71df","topicName":"HIV infection and AIDS","slug":"hiv-infection-aids","lastRevised":"Last revised in July 2020","chapters":[{"id":"a83635cf-fad1-569e-8fec-1e53dd8ae096","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"21903de2-55a7-5de1-8f40-7d516cf2a7ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"34d5dabb-0626-5dfe-9e0a-07e7dac0ec58","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"996367e5-1657-59c5-9c56-45a1e1013995","slug":"changes","fullItemName":"Changes"},{"id":"e5a3550d-1cdf-573d-b498-dc61010e00ab","slug":"update","fullItemName":"Update"}]},{"id":"e6ed5291-d099-5df0-8884-8a42f12be67c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"da045857-e127-5b13-806b-efd61a584eed","slug":"goals","fullItemName":"Goals"},{"id":"f469da13-a03c-5ee1-94e5-b8eafe0a4710","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c9fb3313-7788-5815-b332-9c471eca306c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"63177a9d-218c-57dc-b3b2-7ed72c934d64","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cee63c61-94d3-58f8-baf1-490fff9ea45c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c8f3f309-15a8-577b-a923-a9df302e83dc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5280ae8d-7f20-59e3-9659-6d5e8ee732d9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"77dcc0b6-d3f2-5853-af16-2b7fe5c92758","slug":"definitions","fullItemName":"Definitions"},{"id":"2ebcd00e-1208-5405-bf59-2bcb374d5cbf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9568c950-bbaa-5f5f-aec3-01eb3d3f1cad","slug":"transmission-of-hiv-infection","fullItemName":"Transmission of HIV infection"},{"id":"d63a1c6b-b5d0-585d-b2bd-32d7585a1348","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"a37da596-8c70-54d6-a7c0-b3ff5e433932","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a8377091-e41a-5f81-ac03-60a09edc5331","slug":"complications","fullItemName":"Complications"}]},{"id":"86f39b6e-86fd-5704-81c5-1d7bc804e489","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6937cde7-2e91-5c9f-943e-a3772fdf8fff","slug":"symptomatic-hiv-infection","fullItemName":"Symptomatic HIV infection"},{"id":"bb429eff-4661-5c71-bccb-6c98e9738ee7","slug":"asymptomatic-hiv-infection","fullItemName":"Asymptomatic HIV infection"}]},{"id":"34037594-c7af-59e7-b51e-d4252ee167e2","fullItemName":"Management","slug":"management","subChapters":[{"id":"52deca6b-97b2-52f6-8f9b-734f8717e443","slug":"new-hiv-diagnosis","fullItemName":"Scenario: New HIV diagnosis"},{"id":"10c2085e-ef4b-579a-994f-267109c1bfb5","slug":"acute-hiv-related-problems","fullItemName":"Scenario: Acute HIV-related problems"},{"id":"4c89980b-d988-5bb0-97eb-85427710fb28","slug":"established-hiv-infection","fullItemName":"Scenario: Established HIV infection"},{"id":"fbe0aece-9feb-59c8-8a0e-b822d115f38c","slug":"post-exposure-prophylaxis","fullItemName":"Scenario: Post-exposure prophylaxis"}]},{"id":"5e2f04ec-05b3-5cf1-a129-77b19bc1c3fb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"b7b51785-6622-5495-ab3a-eaf744121195","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0d080358-7d15-5c10-9583-e229d17ecc83","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e3da2b1c-f5c2-51bc-a4af-783d017c48ed","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"275bacfc-149b-5bad-aeb5-3b04ee60f812","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e73775d9-24cb-5d49-86c5-7394e52ada27","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e580fed6-5846-5aef-9890-4b21946b4ffb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"72914ee0-80fc-59a4-8670-236701fce130","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"34037594-c7af-59e7-b51e-d4252ee167e2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"6c3e5c92-2d51-5098-b9ee-0f1598f0c7ec","slug":"review-in-primary-care","fullItemName":"Review in primary care","depth":3,"htmlHeader":"<!-- begin field edff13c2-a822-46fa-a135-3a6f4fc0ff24 --><h3>Review in primary care</h3><!-- end field edff13c2-a822-46fa-a135-3a6f4fc0ff24 -->","summary":null,"htmlStringContent":"<!-- begin item 0b4c72b9-ab28-4d4a-847f-ae11d57a06a8 --><!-- begin field 25f65f45-073b-4233-adfc-0648ac75cce8 --><ul><li><strong>People with HIV attending primary care may require: </strong><ul><li>Advice about sources of <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/new-hiv-diagnosis/#sources-of-information-support\">information and support</a>.</li><li>Information on <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#health-promotion-screening-immunization\">health promotion, screening, and immunization</a>.</li><li>Information on <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#sexual-reproductive-health\">sexual and reproductive health</a>.</li><li>Management of <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#mental-health\">mental health issues</a>.</li><li>Management of <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/acute-hiv-related-problems/\">HIV-related problems</a>.</li><li>Support for <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#end-stage-advanced-hiv-disease\">end-stage advanced HIV</a> disease.</li></ul></li><li><strong>Ensure that the person is <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#non-attenders\">attending specialist services</a>, wherever possible.</strong><ul><li>Monitoring of HIV infection is carried out in specialist clinics using the <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#tests-to-monitor-hiv-infection\">CD4 count and viral load</a>.</li><li>If non-adherence to antiretroviral therapy (ART) is suspected (such as treatment discontinuation or repeatedly missed doses), explain that:<ul><li>Non-adherence can lead to progression to advanced HIV infection, and death.</li><li>Non-adherence can lead to treatment resistance, which is irreversible — this can happen quickly, within 1 week for some ART, and may result in more complex drug regimens being needed.</li></ul></li><li>Seek advice from the person’s HIV specialist if non-adherence is a problem.</li></ul></li><li><strong>Be alert for <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#adverse-effects-of-antiretroviral-therapy\">problems with ART</a>:</strong><ul><li>ART can have serious adverse effects and interact with many other drugs, dietary substances, herbal remedies, and recreational drugs:<ul><li>Take a detailed medication history including over-the-counter and recreational drugs, and complementary therapy/herbal remedies.</li><li>Do not discontinue or adjust the dose of ART without specialist advice.</li><li>Check for potential interactions before starting or stopping any other drug. Information on potential interactions can be obtained from an online interactions database (<a href=\"http://www.hiv-druginteractions.org/\" data-hyperlink-id=\"f7f4671e-f78a-4ef0-b185-abf400cd36db\">www.hiv-druginteractions.org</a>), the British National Formulary (<a href=\"http://www.bnf.org/\" data-hyperlink-id=\"9ecbe76e-5415-4515-9bf4-abf400cd3867\">www.bnf.org</a>), and the drug manufacturers' Summaries of Product Characteristics (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"497f45f7-ba45-494e-b7cf-abf400cd38aa\">www.medicines.org.uk</a>).</li></ul></li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#adverse-effects-of-antiretroviral-therapy\">Adverse effects of antiretroviral therapy</a>.</li><li>If in doubt, seek specialist advice.</li></ul></li></ul><!-- end field 25f65f45-073b-4233-adfc-0648ac75cce8 --><!-- end item 0b4c72b9-ab28-4d4a-847f-ae11d57a06a8 -->","subChapters":[{"id":"d544579d-050d-5687-b792-c5dfb6d1d358","slug":"tests-to-monitor-hiv-infection","fullItemName":"Tests to monitor HIV infection","depth":4,"htmlHeader":"<!-- begin field b4e4a918-3c38-40a5-aea0-e54bb31ae7b7 --><h4>What tests are used to monitor the progress of HIV infection?</h4><!-- end field b4e4a918-3c38-40a5-aea0-e54bb31ae7b7 -->","summary":null,"htmlStringContent":"<!-- begin item 85d1a8d7-0ec8-43eb-81f8-e8147ab90633 --><!-- begin field a5e755a3-54f1-4fec-b00c-a37def3cf319 --><p><strong>Monitoring of HIV is usually carried out in specialist clinics using the CD4 lymphocyte cell (CD4) count and viral load.</strong></p><ul><li><strong>CD4 count</strong><ul><li>The CD4 count reflects the degree of immunosuppression in people infected with HIV — see Table 1 for further information.</li><li>In a healthy person not infected with HIV, the CD4 count is usually greater than 500 cells per microlitre — some people may have naturally lower counts.</li><li>People with CD4 counts below 200 cells per microlitre are most at risk of HIV-related opportunistic infections and cancers. If treatment is started at CD4 counts above 500 cells per microlitre, rather than later, prognosis is improved.</li></ul></li><li><strong>Viral load</strong><ul><li>Viral load reflects rates of viral replication and is measured using a polymerase chain reaction (PCR) test.</li><li>A rising viral load may indicate non-adherence to ART, resistance to one or more antiretroviral drugs, or an interaction with another medication.</li><li>Viral load ranges from undetectable (less than 20–50 copies of viral genome/mL blood) to over a million copies/mL.</li><li>The degree of viral replication is linked to the rate of CD4 decline and therefore disease progression — when viral load is suppressed through ART, CD4 counts recover and risk of HIV-related opportunistic infections and cancers declines.</li></ul></li></ul><p><strong>Table 1.</strong> Correlation of CD4 count with risk of HIV-related opportunistic infections and cancers.</p><table data-table-id=\"5b215086-ac3c-4012-8f36-acce014f7384\"><thead><tr><th colspan=\"1\">CD4 count (cells per microlitre)</th><th colspan=\"1\">Risk of opportunistic infection</th><th colspan=\"1\">Risk of HIV-related cancers</th><th colspan=\"1\">Direct HIV effects</th></tr></thead><tbody><tr><td colspan=\"1\">500 and below</td><td colspan=\"1\">Little risk</td><td colspan=\"1\"><p>Hodgkin's lymphoma</p><p>Cervical cancer</p></td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">400 and below</td><td colspan=\"1\"><p>Bacterial skin infections</p><p>Recurrent bacterial chest infections</p><p>Tuberculosis</p><p>Oropharyngeal candida</p><p>Fungal infections</p><p>Seborrhoeic dermatitis</p></td><td colspan=\"1\"> </td><td colspan=\"1\"><p>Lymphadenopathy</p><p>Sweats</p></td></tr><tr><td colspan=\"1\">350 and below</td><td colspan=\"1\"><p>Oral hairy leukoplakia</p><p>Shingles</p><p>Pneumocystis pneumonia</p><p>Persistent herpes simplex infection</p></td><td colspan=\"1\">Non-Hodgkin's lymphoma</td><td colspan=\"1\">Weight loss</td></tr><tr><td colspan=\"1\">200 and below</td><td colspan=\"1\"><p>Oesophageal candida</p><p>Histoplasmosis</p><p>Cryptococcal meningitis</p><p>Cerebral toxoplasmosis</p><p>Cryptosporidiosis</p></td><td colspan=\"1\">Kaposi's sarcoma</td><td colspan=\"1\"><p>Diarrhoea</p><p>Wasting</p></td></tr><tr><td colspan=\"1\">100 and below</td><td colspan=\"1\"><p>Cytomegalovirus infections</p><p>Atypical mycobacterium infections</p></td><td colspan=\"1\">Primary cerebral lymphoma</td><td colspan=\"1\">Dementia</td></tr><tr><td colspan=\"4\"><strong>From:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>]</td></tr></tbody></table><!-- end field a5e755a3-54f1-4fec-b00c-a37def3cf319 --><!-- end item 85d1a8d7-0ec8-43eb-81f8-e8147ab90633 -->","subChapters":[]},{"id":"08e333ca-23c0-5cd4-92f3-40097c3a928b","slug":"antiretroviral-therapy","fullItemName":"Antiretroviral therapy","depth":4,"htmlHeader":"<!-- begin field 00ab343b-80fb-4682-b1a0-1c34df2a7c2d --><h4>Antiretroviral therapy</h4><!-- end field 00ab343b-80fb-4682-b1a0-1c34df2a7c2d -->","summary":null,"htmlStringContent":"<!-- begin item 65f2c4c8-a6c6-4a64-8084-907d8a45b7d3 --><!-- begin field 4da67060-239a-419d-a4fe-ede727bce981 --><p><strong>Antiretroviral therapy (ART) has had a huge positive impact on HIV-related morbidity and mortality and aims to reduce viral load to undetectable levels by limiting viral replication</strong>.</p><ul><li>HIV mutates as it replicates so drugs are usually used in combinations of three or more to reduce drug resistance.</li><li>Antiretroviral drugs are classified into five groups depending on how they act:<ul><li>Nucleoside/tide reverse transcriptase inhibitors (NRTIs).</li><li>Non-nucleoside reverse transcriptase inhibitors (NNRTIs).</li><li>Protease inhibitors (PIs).</li><li>Integrase inhibitors (IIs).</li><li>Entry inhibitors (EIs).</li></ul></li><li>Specialist blood tests may be used to identify drug resistance and tailor ART regimens accordingly.</li><li>ART suppresses viral replication but does not eliminate HIV therefore treatment is lifelong.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Samuel, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018a</a>]</p><!-- end field 4da67060-239a-419d-a4fe-ede727bce981 --><!-- end item 65f2c4c8-a6c6-4a64-8084-907d8a45b7d3 -->","subChapters":[]},{"id":"4daef3e3-9ea1-52d1-abbc-07a5afc34d71","slug":"adverse-effects-of-antiretroviral-therapy","fullItemName":"Adverse effects of antiretroviral therapy","depth":4,"htmlHeader":"<!-- begin field 45a95f26-a1fd-4750-8313-6f9b12d36ff7 --><h4>Adverse effects of antiretroviral therapy</h4><!-- end field 45a95f26-a1fd-4750-8313-6f9b12d36ff7 -->","summary":null,"htmlStringContent":"<!-- begin item e151efa9-9e79-4549-8af9-f8d3ef8b68bb --><!-- begin field 212c4e07-90b8-4a41-a8b1-e26a42bb2e22 --><p><strong>Antiretroviral therapy (ART) can have multiple adverse effects, some of which can be serious or life threatening </strong>— adverse effects are most common with older classes of drugs but all have potential short- and long-term toxic effects.</p><ul><li><strong>Consider whether specialist advice or hospital <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/acute-hiv-related-problems/#who-should-i-admit\">admission</a> is required. </strong><ul><li>Do not stop any ART or adjust the dose without specialist advice.</li><li>Be aware that some minor adverse effects may herald a major adverse effect, and have a low threshold for seeking specialist advice.</li><li>Serious adverse effects may present in unusual ways such as osteoporosis, Fanconi syndrome, or lactic acidosis.</li></ul></li><li><strong>Adverse effects include:</strong><ul><li>Hypersensitivity.<ul><li>Typically causes fever or rash but can cause non-specific symptoms such as fever, vomiting, or myalgia. Hypersensitivity can be life threatening — seek urgent advice if suspected.</li></ul></li><li>Neurological and psychiatric conditions.<ul><li>Nightmares, sleep disturbance, mood or behaviour changes may occur; psychosis and suicidal ideation have also been reported.</li><li>Peripheral neuropathy.</li></ul></li><li>Hyperlipidaemia (common).<ul><li>Rises in cholesterol or triglycerides can be extreme, lipids need to be regularly monitored and managed.</li><li>Drug interactions with statins and fibrates occur frequently and can be serious — seek specialist advice before prescribing.</li></ul></li><li>Lipodystrophy (changes in the distribution of body fat) and lipoatrophy (loss of subcutaneous fat).<ul><li>These may be associated with diabetes, and hyperlipidaemia.</li></ul></li><li>Type 2 diabetes mellitus.<ul><li>This most likely occurs through insulin resistance and can be associated with ART.</li></ul></li><li>Bone density loss.<ul><li>People with HIV are at higher risk of osteopenia, osteoporosis, and fractures — this is likely due to a combination of factors such as ART, lifestyle, and previous steroid treatment.</li></ul></li><li>Renal problems.<ul><li>A decline in renal function may indicate Fanconi’s syndrome (dysfunction of the proximal tubule) — seek specialist advice.</li><li>Ureteric colic, renal and ureteric stones may also occur.</li></ul></li><li>Lactic acidosis and hepatic toxicity.<ul><li>May present with non-specific symptoms such as nausea, anorexia, or abdominal pain — potentially life threatening.</li></ul></li><li>Peripheral neuropathy.</li><li>Bone marrow suppression.</li><li>Pancreatitis.<ul><li>Most often associated with older ART.</li></ul></li></ul></li><li><strong>For a full list of adverse effects see the <a href=\"http://www.bnf.org/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"7c8aa6eb-1216-47c7-abe6-abf900ab56f2\">British National Formulary</a>.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Lebari, 2019</a>]</p><!-- end field 212c4e07-90b8-4a41-a8b1-e26a42bb2e22 --><!-- end item e151efa9-9e79-4549-8af9-f8d3ef8b68bb -->","subChapters":[]},{"id":"f949d232-2c2f-5643-836c-b19d4f16512d","slug":"basis-for-recommendation-610","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6730aaaa-72a6-47ac-ae75-6fbaa133d2ea --><h4>Basis for recommendation</h4><!-- end field 6730aaaa-72a6-47ac-ae75-6fbaa133d2ea -->","summary":null,"htmlStringContent":"<!-- begin item 610d6c7c-b958-499d-985a-8984fdca0b7d --><!-- begin field ee0e67ac-cc15-4b41-86dd-e62fb56a45a3 --><p>These recommendations are based on the clinical guidelines <em>BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2016</a>], <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>], and <em>Standards of care for people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018a</a>]; and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Samuel, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Goldschmidt, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Chu, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Lebari, 2019</a>].</p><!-- end field ee0e67ac-cc15-4b41-86dd-e62fb56a45a3 --><!-- end item 610d6c7c-b958-499d-985a-8984fdca0b7d -->","subChapters":[]}]},{"id":"10e293ff-f4f2-54d1-9676-51a80d0f96de","slug":"health-promotion-screening-immunization","fullItemName":"Health promotion, screening, and immunization","depth":3,"htmlHeader":"<!-- begin field 9162cc5e-184f-49b5-94e0-90f7e61df55d --><h3>Health promotion</h3><!-- end field 9162cc5e-184f-49b5-94e0-90f7e61df55d -->","summary":null,"htmlStringContent":"<!-- begin item 11d16fdc-52fd-4ca6-8506-79ff4409e9dc --><!-- begin field 1bbf7dd0-70a8-478e-83f5-b1a38db161ff --><h4>Cardiovascular disease (CVD) prevention</h4><ul><li>People living with HIV are at higher risk of metabolic abnormalities (such as dyslipidaemia and insulin resistance) and cardiovascular disease.</li><li>Preventative measures such as lifestyle advice on diet, exercise, alcohol reduction and smoking cessation, blood pressure monitoring, and screening for diabetes and hyperlipidaemia should be offered.</li><li>CVD risk assessment and initiation of treatment is usually carried out by specialist services but may be indicated in primary care.<ul><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li><li>Be aware that statins (especially simvastatin) and fibrates can have serious drug interactions with some antiretroviral therapy (ART).</li><li>Check the HIV drug interaction website <a href=\"http://www.hiv-druginteractions.org/\" data-hyperlink-id=\"6d07e537-46bd-4756-8d5a-abf400cfe448\">www.hiv-druginteractions.org</a> and seek expert advice before initiating any treatment.</li></ul></li></ul><h4>Cervical screening</h4><ul><li>HIV infection increases the risk of cervical cancer.</li><li>All women with newly diagnosed HIV should have performed by, or in conjunction with, their HIV specialist team:<ul><li>Initial colposcopy following diagnosis.</li><li>Annual cytology.</li></ul></li></ul><h4>Immunizations</h4><ul><li>Ensure the person is up to date with immunizations.<ul><li>Up-to-date information on specific vaccines is available from the British HIV Association <a href=\"https://www.bhiva.org/vaccination-guidelines\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"7f8ba636-f9e3-4326-8038-abf900ad98f4\">Guidelines on the use of vaccines in HIV-positive adults (2015)</a>.</li><li>Seek advice if unsure and always check with the person’s HIV specialist before administering vaccinations.</li><li>People with HIV infection should not usually receive live vaccines such as BCG (Bacille Calmette–Guérin), cholera, or oral typhoid immunization.</li></ul></li><li>Seek paediatric specialist advice about immunizing children with HIV (or children who have a parent with HIV).</li></ul><h4>International travel</h4><ul><li>Entry restrictions<ul><li>Some countries restrict entry for people with HIV (see <a href=\"http://www.hivtravel.org/\" data-hyperlink-id=\"f39df877-efcf-479c-88b2-abf400cfe498\">www.hivtravel.org</a> for further information).</li><li>Advise the person to check with the relevant embassies before travel.</li></ul></li><li>Vaccinations<ul><li>For more information on which immunizations are advised before travelling, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-travel/\">Immunizations - travel</a>. Up-to-date guidance on the use of vaccines in HIV-positive adults is available on the <a href=\"https://www.bhiva.org/vaccination-guidelines\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"d6f7d142-e261-46cf-843d-abf900ad9941\">British HIV Association</a> website.</li><li>Always check about the safety of administering a vaccine with specialist services.</li></ul></li><li>Malaria prophylaxis<ul><li>Advise the person that malaria prophylaxis can be used but may interact with ART.</li><li>For further information, see the HIV drug interactions website (<a href=\"http://www.hiv-druginteractions.org/\" data-hyperlink-id=\"80952ab0-8ade-49e7-8a43-abf400cfe4c1\">www.hiv-druginteractions.org</a>) and seek specialist advice before prescribing.</li></ul></li><li>Advise the person:<ul><li>On <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/established-hiv-infection/#sexual-reproductive-health\">safer sexual practices</a> where appropriate.</li><li>To take a summary of past medical history and prescribed drugs in case they become unwell abroad.</li></ul></li></ul><!-- end field 1bbf7dd0-70a8-478e-83f5-b1a38db161ff --><!-- end item 11d16fdc-52fd-4ca6-8506-79ff4409e9dc -->","subChapters":[{"id":"0b6b5f52-73ed-5be0-b46b-fda516d3e1da","slug":"basis-for-recommendation-69c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5f348f4d-57f3-4e4f-b44c-68bc8709d9d0 --><h4>Basis for recommendation</h4><!-- end field 5f348f4d-57f3-4e4f-b44c-68bc8709d9d0 -->","summary":null,"htmlStringContent":"<!-- begin item 69ceeb88-96a1-4436-90fd-89a7e0648b5c --><!-- begin field 1dec4098-6d04-4027-95d9-cb91eeb61eaa --><p>Recommendations are based on the clinical guidelines <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>], <em>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2016 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>], <em>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommendations for a public health approach - Second edition</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016a</a>], <em>BHIVA/BASHH/FSRH guidelines for the sexual and reproductive health of people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>], <em>Standards of care for people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018a</a>], and <em>BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2019a</a>]; and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Feinstein, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Lebari, 2019</a>].</p><h5>Immunizations</h5><ul><li>Detailed up-to-date evidence-graded recommendations on the appropriate use of active and passive immunization in HIV-infected adults and children are available from:<ul><li>The Children’s HIV Association (CHIVA) — <a href=\"https://www.chiva.org.uk/files/8315/4453/4519/Vaccination_of_HIV_infected_children_2018.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"71e98a54-265c-4fe4-8b07-abf900aeb24e\">Vaccination of HIV infected children (UK schedule, 2018)</a>.</li><li>The British HIV Association (BHIVA) — <a href=\"https://www.bhiva.org/vaccination-guidelines\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"233f5a63-d58d-4bb9-8f6c-abf900aeb270\">Guidelines on the use of vaccines in HIV-positive adults (2015)</a>.</li></ul></li></ul><!-- end field 1dec4098-6d04-4027-95d9-cb91eeb61eaa --><!-- end item 69ceeb88-96a1-4436-90fd-89a7e0648b5c -->","subChapters":[]}]},{"id":"78cd158a-f61e-57ea-99df-7f6fb777dc2f","slug":"sexual-reproductive-health","fullItemName":"Sexual and reproductive health","depth":3,"htmlHeader":"<!-- begin field bec594de-6040-4738-a707-df44562b06c5 --><h3>Sexual and reproductive health</h3><!-- end field bec594de-6040-4738-a707-df44562b06c5 -->","summary":null,"htmlStringContent":"<!-- begin item 003d2aba-03bd-4445-b261-417888a43057 --><!-- begin field ec1949cf-3220-4344-9e09-e141a369d8b0 --><h4>Use of condoms</h4><ul><li>Advise the person on consistent and correct use of condoms and lubricant to reduce the risk of HIV transmission and other sexually transmitted infections (STIs).<ul><li>For optimal contraception condoms should always be used with an additional contraceptive method.</li><li>Oil-based lubricants should not be used with latex condoms as they damage latex — advise the person to use water- or silicone-based lubricants.</li><li>Condoms lubricated with the spermicide nonoxinol-9 (N-9) should not be used as this may increase the risk of genital lesions and as a result HIV acquisition or transmission.</li></ul></li><li>Condoms should still be used even if:<ul><li>Antiretroviral therapy (ART) is taken regularly and viral load suppressed.</li><li>The person's partner is also HIV positive (to prevent drug-resistant strains from being transferred).</li></ul></li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-barrier-methods-spermicides/\">Contraception - barrier methods and spermicides</a>.</li></ul><h4>Sexual health screening</h4><ul><li>STIs in either partner may increase the risk of HIV transmission.</li><li>Advise the person on the importance of regular STI screening.</li></ul><h4>Pre-exposure prophylaxis (PrEP)</h4><ul><li>PrEP is a combination of two antiretroviral drugs that are taken before and after sex to reduce the risk of HIV acquisition – it is offered on a case by case basis to HIV-negative people who are at high risk of HIV and who do not always use condoms.<ul><li>Signpost to a sexual health clinic people who may be eligible for PrEP — baseline HIV testing, counselling on risks and benefits, support to improve adherence, and regular HIV and STI screening is required.</li><li>Be aware that some medication regimens may have serious interactions with other drugs.</li></ul></li><li>Availability of PrEP varies geographically — information about PrEP and how to access PrEP in the UK is available online:<ul><li>For England at <a href=\"http://www.prepimpacttrial.org.uk/\" data-hyperlink-id=\"880d72ce-70bc-463c-8e9b-abf400d04bb7\">www.prepimpacttrial.org.uk</a>.</li><li>For Northern Ireland at <a href=\"http://www.sexualhealthni.info/pre-exposure-prophylaxis-prep-hiv\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"bc5ddfa5-0282-4950-878e-abf900b0b6eb\">www.sexualhealthni.info/pre-exposure-prophylaxis-prep-hiv</a>.</li><li>For Scotland at <a href=\"https://prep.scot/\" data-hyperlink-id=\"52036f80-7035-4a28-80ce-abf400d04bfa\">https://prep.scot/</a>.</li><li>For Wales at <a href=\"http://www.friskywales.org/wales-prep-project.html\" data-hyperlink-id=\"e00b3abd-b505-41ea-973a-abf400d04c49\">www.friskywales.org/wales-prep-project.html</a>.</li></ul></li></ul><h4>Post-exposure prophylaxis</h4><ul><li>For information on post-exposure prophylaxis (PEP), see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hiv-infection-aids/management/post-exposure-prophylaxis/\">Post-exposure prophylaxis for HIV</a>.</li><li>Be aware that PEP following sexual exposure is no longer recommended if a HIV-negative partner has unprotected sexual intercourse with an HIV-positive person who has a sustained undetectable viral load.<ul><li>PEP <em>is </em>needed following sexual intercourse if a HIV-negative partner is exposed to HIV and there are any ART adherence issues, or if viral loads are unsuppressed or not being actively monitored.</li></ul></li></ul><h4>Contraception</h4><ul><li>Contraceptive choice for women with HIV may be complicated by potential drug interactions with ART — seek specialist advice.<ul><li>Oral contraceptives and patches may have reduced effectiveness with some ART combinations.</li><li>Long-acting reversible contraceptives such as the copper intrauterine device (Cu-IUD), the levonorgestrel-releasing intrauterine system (IUS), or depot medroxyprogesterone acetate (DMPA) injection do not appear to be affected by enzyme-inducing drugs.</li></ul></li><li>Emergency contraception.<ul><li>Seek specialist advice — for women on liver enzyme-inducing ART:<ul><li>A Cu-IUD is the recommended method of emergency contraception except in women with a CD4 less than 200 cells per microlitre and detectable HIV RNA (owing to potential higher risk of infection post procedure).</li><li>If progesterone-only emergency contraception is used, a doubling of the standard dose may be advised (off-label).</li></ul></li></ul></li></ul><h4>Fertility and assisted conception</h4><ul><li>Specialist fertility services input is recommended for all couples who wish to conceive where one or both partners are living with HIV.</li><li>Options vary depending on concordance, treatment, and viral suppression and may include donor insemination, sperm washing, or self insemination.</li></ul><h4>Antenatal and postnatal care</h4><ul><li>Care should be provided through antenatal multi-disciplinary team including an HIV specialist, obstetrician, specialist midwife, and paediatrician.</li><li>Risk of transmitting HIV from mother to child in pregnancy can be reduced from around 20% to less than 1% by:<ul><li>Taking ART during pregnancy.</li><li>Using ART at the time of delivery, together with a short course of ART for the newborn baby.</li><li>Vaginal delivery for women on ART who have an undetectable viral load or elective Caesarean section for others.</li><li>Avoidance of breastfeeding — be aware that avoidance of breastfeeding may lead to problems with speculation about, or even disclosure of, the mother’s HIV status. Advice and support should be available.</li></ul></li></ul><h4>Menopause</h4><ul><li>Management of menopause in women living with HIV should be in line with <a href=\"https://www.nice.org.uk/guidance/NG23\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"4ffc4ab6-2680-44dd-a2e6-abf900b0b772\">NICE guidance</a>, however, specialist input is indicated as there may be drug interactions with some ART and commonly used menopause treatments.</li></ul><p>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.</p><!-- end field ec1949cf-3220-4344-9e09-e141a369d8b0 --><!-- end item 003d2aba-03bd-4445-b261-417888a43057 -->","subChapters":[{"id":"f7801d1e-e5a6-5247-8b8d-87ddf078dc71","slug":"basis-for-recommendation-eb5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 97492a7e-4b6e-4fed-8b2c-6f5de3f6375f --><h4>Basis for recommendation</h4><!-- end field 97492a7e-4b6e-4fed-8b2c-6f5de3f6375f -->","summary":null,"htmlStringContent":"<!-- begin item eb503faf-52de-479c-b8c3-3d16fd661e63 --><!-- begin field c5441f8a-8dcb-408c-9d49-51a521f77816 --><p>These recommendations are based on the clinical guidelines <em>Barrier methods for contraception and STI prevention</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">FSRH, 2015</a>], <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>], <em>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2016 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>], <em>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016a</a>], <em>BHIVA/BASHH/FSRH guidelines for the sexual and reproductive health of people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>], <em>Standards of care for people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018a</a>], and <em>British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2019 second interim update)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2019c</a>]; and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Goldschmidt, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Bamford, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Saag, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BMJ Best Practice, 2020a</a>].</p><h5>Use of condoms</h5><ul><li>The recommendations on use of condoms are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">FSRH, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Saag, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BMJ Best Practice, 2020a</a>].</li><li>Use of lubricant is recommended for anal sex to reduce the risk of condom breakage. In terms of condom safety, there is insufficient evidence to routinely advise additional lubricant for vaginal sex, but it can be considered for those experiencing condom breakage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">FSRH, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>].</li></ul><h5>Sexual health screening</h5><ul><li>The recommendations on sexual health screening are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2019a</a>].</li><li>Public Health England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">PHE, 2016</a>] recommend that men who have sex with men should have HIV and sexually transmitted infection screening at least annually and every 3 months if having unprotected anal intercourse with casual or new sexual partners.</li></ul><h5>Pre-exposure prophylaxis</h5><ul><li>The information on pre-exposure prophylaxis is based on the clinical guidance <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>], <em>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2016 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>], and <em>BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018b</a>]; the Public Health England report <em>HIV in the United Kingdom. Towards zero HIV transmissions by 2030. 2019 report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">PHE, 2019b</a>]; and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Tumarkin, 2019</a>].</li><li>The British HIV Association (BHIVA) and British Association for Sexual Health and HIV (BASHH) recommend that pre-exposure prophylaxis (PrEP) is offered on a case by case basis to people at ongoing high risk of acquiring HIV as this has been shown to be highly effective in preventing HIV in some risk groups [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018b</a>].</li><li>Specialist input at initiation and for ongoing monitoring is required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018b</a>].</li><li>Primary care is not expected to issue PrEP but should contribute to the broader HIV prevention strategy through HIV testing, provision of condoms, encouraging adherence to antiretroviral therapy for those tested positive, and discussion about PrEP where available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018a</a>].</li></ul><h5>Contraception</h5><ul><li>Recommendations on contraception are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>].</li></ul><h5>Fertility and assisted conception</h5><ul><li>Recommendation on fertility and assisted conception are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>].</li></ul><h5>Antenatal and postnatal care</h5><ul><li>Recommendations on antenatal and postnatal care are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">CHIVA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2019c</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Bamford, 2018</a>].</li><li>Information on reducing risk of mother to child HIV transmission in pregnancy is taken from clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">CHIVA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2019c</a>].</li><li>BHIVA recommends that in the UK, the safest way to feed infants born to women with HIV is with formula milk, as there is no on-going risk of HIV exposure after birth. Guidance notes that avoidance of breastfeeding can have financial and psychological repercussions for women — support from the HIV multi-disciplinary team should be available. Women advised not to breastfeed for their baby’s health should be provided with free formula feed to minimize vertical transmission of HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2019c</a>].</li></ul><h5>Menopause</h5><ul><li>Recommendations on menopause are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>].</li><li>Evidence on the best management strategies for menopausal women living with HIV (including the efficacy and safety of hormone replacement therapy [HRT]) are lacking — management in line with current National Institute for Health and Care Excellence (NICE) menopause guidelines are recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2017</a>].</li></ul><!-- end field c5441f8a-8dcb-408c-9d49-51a521f77816 --><!-- end item eb503faf-52de-479c-b8c3-3d16fd661e63 -->","subChapters":[]}]},{"id":"a991396c-4404-534a-8e85-559c81370b50","slug":"mental-health","fullItemName":"Mental health","depth":3,"htmlHeader":"<!-- begin field 5557ffd2-ca4a-4477-88a9-125c879416f2 --><h3>Mental health</h3><!-- end field 5557ffd2-ca4a-4477-88a9-125c879416f2 -->","summary":null,"htmlStringContent":"<!-- begin item b147c919-e83c-4afd-a426-08ce6180dc22 --><!-- begin field cbc6ac3a-b8a2-4cc4-ac26-d45b22f70c97 --><ul><li><strong>People with HIV are at greater risk of mental health problems </strong>(such as depression, anxiety, and substance abuse) than the general population. This may be because:<ul><li>People with pre-existing mental health conditions may be more likely to engage in high-risk activities.</li><li>People with HIV may suffer stigma, isolation, and discrimination making them more likely to suffer from depression or anxiety.</li><li>Some HIV drugs may be associated with mental health symptoms.</li></ul></li><li>Mental health conditions should be assessed and managed as usual, referring to specialist mental health services where appropriate.<ul><li>Many drug treatments used to treat mental health conditions have serious interactions with antiretroviral therapy (ART) — seek specialist advice before prescribing.</li></ul></li><li>For further information on depression and anxiety, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li></ul><!-- end field cbc6ac3a-b8a2-4cc4-ac26-d45b22f70c97 --><!-- end item b147c919-e83c-4afd-a426-08ce6180dc22 -->","subChapters":[{"id":"605895dc-7e99-5062-96b8-8d5ded39337e","slug":"basis-for-recommendation-2bd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b31bd603-0cfd-4c38-92c7-dc8d1959a3e2 --><h4>Basis for recommendation</h4><!-- end field b31bd603-0cfd-4c38-92c7-dc8d1959a3e2 -->","summary":null,"htmlStringContent":"<!-- begin item 2bddc27c-be1e-4c2b-af26-29c40cd1bef2 --><!-- begin field 8bd527d6-3f92-4631-bcb2-88ccbd4a7e69 --><p>These recommendations are based on the clinical guidelines <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>], <em>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2016 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">WHO, 2016b</a>], and <em>Standards of care for people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018c</a>].</p><!-- end field 8bd527d6-3f92-4631-bcb2-88ccbd4a7e69 --><!-- end item 2bddc27c-be1e-4c2b-af26-29c40cd1bef2 -->","subChapters":[]}]},{"id":"0fe729e3-aea6-5490-b368-717e49a39939","slug":"non-attenders","fullItemName":"Non-attenders","depth":3,"htmlHeader":"<!-- begin field d8bb00dd-66b6-444a-8fde-a9c90a57ec18 --><h3>How should I support a person to attend specialist services?</h3><!-- end field d8bb00dd-66b6-444a-8fde-a9c90a57ec18 -->","summary":null,"htmlStringContent":"<!-- begin item dd3d0777-1666-4dc0-ac3f-16d2a953556c --><!-- begin field 0bc46eb3-b016-4a18-9caa-b6a9d8c4521d --><ul><li>Some people with HIV infection may not attend for specialist care — this may be owing to problems with antiretroviral therapy (ART), belief that treatment is no longer needed, HIV-related stigma, mental health conditions, or socioeconomic difficulties.</li><li>If the person is not attending specialist services regularly:<ul><li>Confirm that the patient has capacity to make decisions.</li><li>Explore their reasons for not attending — problems such as fear of being recognized at a local clinic may be addressed by changing to a geographically different service.</li><li>Reinforce the benefits of attending specialist care.</li><li>Consider, after discussion with the person's specialist and the local laboratory, assessing immunity by checking a CD4 count in primary care.</li><li>Discuss with the person's specialist the option of prophylactic treatment against some opportunistic infections such as pneumocystis pneumonia.</li></ul></li></ul><!-- end field 0bc46eb3-b016-4a18-9caa-b6a9d8c4521d --><!-- end item dd3d0777-1666-4dc0-ac3f-16d2a953556c -->","subChapters":[{"id":"0d72694e-b8dd-50f4-bb58-7bd0f4e770df","slug":"basis-for-recommendation-8e1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 428c8209-e0b3-4c03-92f5-bc5233121724 --><h4>Basis for recommendation</h4><!-- end field 428c8209-e0b3-4c03-92f5-bc5233121724 -->","summary":null,"htmlStringContent":"<!-- begin item 8e17d425-66aa-4bbb-9dce-ee3ae9d41e4c --><!-- begin field a2f7b9ce-4647-4b7f-9c89-e50df6c7b8b7 --><p>These recommendations are based on the clinical guidance <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>].</p><!-- end field a2f7b9ce-4647-4b7f-9c89-e50df6c7b8b7 --><!-- end item 8e17d425-66aa-4bbb-9dce-ee3ae9d41e4c -->","subChapters":[]}]},{"id":"82cdadaf-494f-551b-9cc5-573e23e569b4","slug":"end-stage-advanced-hiv-disease","fullItemName":"End-stage advanced HIV disease","depth":3,"htmlHeader":"<!-- begin field 3ccb8a96-2b7c-4907-8661-7899fb782d8d --><h3>How should I manage end-stage advanced HIV disease?</h3><!-- end field 3ccb8a96-2b7c-4907-8661-7899fb782d8d -->","summary":null,"htmlStringContent":"<!-- begin item 3e913f6f-eb0a-4f09-8f29-95636c5810c2 --><!-- begin field 31de3945-c6fc-4277-95fc-21efa8286fdf --><ul><li><strong>Death as a direct result of HIV-infection is uncommon since the introduction of effective antiretroviral therapy (ART).</strong><ul><li>End-stage advanced HIV disease usually occurs in people who present late or have co-morbidities.</li><li>In people taking ART it can be more difficult to identify terminal illness — immunity may recover following a change in treatment regimen but the risk of overwhelming infection remains until this happens.</li><li>Close communication between secondary and primary care services is particularly important.</li></ul></li><li><strong>Care planning and advance decisions.</strong><ul><li>Discuss care planning and advance decisions if immunity has started to decline — early, sensitive discussion and planning on how best to manage the person's end of life care can help avoid later distress.</li><li>Explain that any decisions are flexible and can change as disease progresses.</li><li>For further information on advance care planning and end of life care see:<ul><li>The CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a>.</li><li>Guidance from the General Medical Council (GMC) on treatment and care towards the end of life, is available on the <a href=\"https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/treatment-and-care-towards-the-end-of-life\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"3351e05f-9956-432f-9685-abf900e10a9c\">GMC website</a>.</li></ul></li></ul></li><li><strong>Palliative care.</strong><ul><li>When palliative care is required, it should be provided by a multi-disciplinary team including the person's HIV specialist, primary care team, palliative care services, and community nursing.</li><li>In some areas specialist community nurses in HIV care are available.</li></ul></li><li><strong>Death certification.</strong><ul><li>If a person is known to have died from an HIV-related illness then this must be stated on the death certificate.</li><li>Confidentiality continues after death and in circumstances where the family do not know about their relative’s HIV status, this can be complicated and should be handled sensitively.</li></ul></li></ul><!-- end field 31de3945-c6fc-4277-95fc-21efa8286fdf --><!-- end item 3e913f6f-eb0a-4f09-8f29-95636c5810c2 -->","subChapters":[{"id":"5ab8bbe0-12c1-5c92-a3e5-e28fdbc4180a","slug":"basis-for-recommendation-415","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d534ee3b-3e7c-4490-a4ba-dcad7102ee43 --><h4>Basis for recommendation</h4><!-- end field d534ee3b-3e7c-4490-a4ba-dcad7102ee43 -->","summary":null,"htmlStringContent":"<!-- begin item 415cd92b-d3a1-4020-8bec-bb2b422f91d3 --><!-- begin field c5983b5f-2a0f-4598-a355-1a2730966c43 --><p>Recommendations are based on the clinical guidelines <em>HIV in primary care. A practical guide for primary healthcare professionals in Europe</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">Matthews, 2016</a>] and <em>Standards of care for people living with HIV</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hiv-infection-aids/references/\">BHIVA, 2018c</a>].</p><!-- end field c5983b5f-2a0f-4598-a355-1a2730966c43 --><!-- end item 415cd92b-d3a1-4020-8bec-bb2b422f91d3 -->","subChapters":[]},{"id":"a56a5392-9d83-51f5-9d55-9d2f1fe04d93","slug":"aids-defining-conditions","fullItemName":"AIDS defining conditions","depth":4,"htmlHeader":"<!-- begin field e5189200-8f13-4150-82a8-abf400ce26bd --><h4>AIDS-defining conditions</h4><!-- end field e5189200-8f13-4150-82a8-abf400ce26bd -->","summary":null,"htmlStringContent":"<!-- begin item 735a67df-56b7-4de9-891b-abf400ce2669 --><!-- begin field ebccce4b-b138-4ae8-9840-abf400ce26bd --><p><strong>The following conditions are considered to be AIDS defining when they occur in people living with HIV</strong><strong>:</strong></p><ul><li><strong>Neoplasms </strong><ul><li>Cervical cancer.</li><li>Non-Hodgkin lymphoma.</li><li>Kaposi’s sarcoma.</li></ul></li><li><strong>Bacterial infections </strong><ul><li><em>Mycobacterium tuberculosis</em>, pulmonary or extrapulmonary.</li><li><em>Mycobacterium avium</em> complex or <em>Mycobacterium kansasii</em>, disseminated or extrapulmonary.</li><li><em>Mycobacterium</em>, other species or unidentified species, disseminated or extrapulmonary.</li><li>Pneumonia, recurrent (two or more episodes in 12 months).</li><li><em>Salmonella</em> septicaemia, recurrent.</li></ul></li><li><strong>Viral infections </strong><ul><li>Cytomegalovirus retinitis.</li><li>Cytomegalovirus, other (except liver, spleen, glands).</li><li>Herpes simplex, ulcer(s) more than 1 month/bronchitis/pneumonitis.</li><li>Progressive multifocal leukoencephalopathy.</li></ul></li><li><strong>Parasitic infections </strong><ul><li>Cerebral toxoplasmosis.</li><li>Cryptosporidiosis diarrhoea, more than 1 month.</li><li>Isosporiasis, more than 1 month.</li><li>Atypical disseminated leishmaniasis.</li><li>Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis).</li></ul></li><li><strong>Fungal infections </strong><ul><li>Pneumocystis pneumonia (PCP).</li><li>Candidiasis, oesophageal.</li><li>Candidiasis, bronchial/tracheal/pulmonary.</li><li>Cryptococcosis, extrapulmonary.</li><li>Histoplasmosis, disseminated/extrapulmonary.</li><li>Coccidioidomycosis, disseminated/extrapulmonary.</li><li>Penicilliosis, disseminated.</li></ul></li></ul><!-- end field ebccce4b-b138-4ae8-9840-abf400ce26bd --><!-- end item 735a67df-56b7-4de9-891b-abf400ce2669 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}